DCAF1 and colonic neoplasm: As a potential therapeutic benefit of using inhibitors targeting histone‐modifying factors has not been well explored, our results also suggest that pharmacological inhibition of VprBP kinase activity is a useful tool to regulate the growth and proliferation of colon cancer cells.